JINGXIN(002020)2025-04-03 09:40Financial Performance - In 2024, the company achieved a total revenue of 4.159 billion CNY, representing a year-on-year growth of 3.99% [2] - Finished drug revenue reached 2.522 billion CNY, with an increase of 8.42% [2] - Raw material drug revenue was 876 million CNY, showing a decline of 8.37% [2] - Medical device revenue amounted to 687 million CNY, growing by 7.84% [2] - The net profit attributable to shareholders was 712 million CNY, up by 15.04% [2] - The net profit after deducting non-recurring items was 647 million CNY, reflecting a growth of 21.38% [2] Product Development - The company submitted a clinical application for the innovative drug JX2201 for treating LP(a) dyslipidemia by the end of 2024 and has initiated Phase I clinical trials [3] - The innovative drug Didasin was officially launched in March 2024 and successfully entered the medical insurance catalog after negotiations in November 2024 [3] Market Performance - The finished drug market outside hospitals experienced rapid growth, increasing by 45% year-on-year in 2024 [3] - The retail division is focused on expanding the outpatient market through collaboration with retail pharmacy chains and enhancing coverage in grassroots pharmacies [3] Sales and Marketing Strategy - The company has achieved a reduction in sales expenses over the past few years through more precise expenditure allocation and improved employee efficiency [3] - In 2025, the company aims to control the sales expense ratio while expanding its market presence in outpatient and grassroots markets [3]